98%
921
2 minutes
20
Background: Face transplantation has emerged as a viable option for certain patients in the treatment of devastating facial injuries. However, as with autologous free tissue transfer, the need for secondary revisions in face transplantation also exists. The authors' group has quantified the number of revision operations in their cohort and has assessed the rationale, safety, and outcomes of posttransplantation revisions.
Methods: A retrospective analysis of prospectively collected data of the authors' seven face transplants was performed from April of 2009 to July of 2015. The patients' medical records, preoperative facial defects, and all operative reports (index and secondary revisions) were critically reviewed.
Results: The average number of revision procedures was 2.6 per patient (range, zero to five procedures). The median time interval from face transplantation to revision surgery was 5 months (range, 1 to 10 months). Most interventions consisted of debulking of the allograft, superficial musculoaponeurotic system plication and suspension, and local tissue rearrangement. There were no major infections, allograft skin flap loss, or necrosis. One patient suffered a postoperative complication after autologous fat grafting in the form of acute rejection that resolved with pulse steroids.
Conclusions: Secondary revisions after face transplantation are necessary components of care, as they are after most conventional free tissue transfers. Secondary revisions after face transplantation at the authors' institution have addressed both aesthetic and functional reconstructive needs, and these procedures have proven to be safe in the context of maintenance immunosuppression. Patient and procedure selection along with timing are essential to ensure patient safety, optimal function, and aesthetic outcomes.
Clinical Question/level Of Evidence: Therapeutic, V.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/PRS.0000000000002605 | DOI Listing |
ESC Heart Fail
September 2025
Division of Heart Failure and Transplant, Mayo Clinic in Florida, Jacksonville, Florida, USA.
Background: Patients with end-stage heart failure and chronic kidney disease requiring dual-organ transplantation (DOT) face significant challenges in utilizing durable mechanical circulatory support due to the risks associated with renal replacement therapies (RRTs) and multi-organ failure. Given the limited options available for long-term support in this patient population, there remains a critical need for alternative strategies to optimize end-organ function and bridge patients safely to transplant. With prolonged waitlist times for DOT, we present our experience with the Impella 5.
View Article and Find Full Text PDFPlast Reconstr Surg
September 2025
Hansjörg Wyss Department of Plastic Surgery, New York University Langone Health, New York, NY, US.
Background: Facial transplantation offers transformative solutions for patients with severe facial disfigurements. Minimizing ischemia time is critical for preserving tissue viability, and prioritizing facial allograft recovery during multi-organ procurement aims to optimize outcomes. This study evaluates whether prioritizing face allograft procurement affects the outcomes of non-vascularized composite allotransplantation (non-VCA) organ transplants.
View Article and Find Full Text PDFTher Adv Hematol
September 2025
Department of Hematology, The Affiliated Hospital of Qingdao University, 16 Jiangsu Road, Qingdao, Shandong 266000, China.
Myelodysplastic syndromes (MDS), particularly in older adults aged 60 years and above, present significant therapeutic challenges due to poor prognosis and limited treatment options. Higher-risk MDS (HR-MDS), defined by the Revised International Prognostic Scoring System score of ⩾3.5, is characterized by increased myeloblasts, severe cytopenia, and a median survival of <2 years.
View Article and Find Full Text PDFZhong Nan Da Xue Xue Bao Yi Xue Ban
May 2025
Nursing Department, Third Xiangya Hospital, Central South University, Changsha 410013.
Objectives: End stage renal disease (ESRD) is a major disease that seriously threatens the health of young people, and kidney transplantation is an effective treatment method to improve its prognosis.Young ESRD patients at a critical stage of life development often face significant physical and psychological challenges while waiting for kidney transplantation. Their psychological state directly affects treatment compliance and transplantation outcomes.
View Article and Find Full Text PDFHum Immunol
September 2025
Division of Cardiovascular Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.
Heart transplant candidates that are highly sensitized against human leukocyte antigens (HLA) face ongoing challenge in finding immunologically compatible donors. Desensitization strategies aimed at reducing HLA antibody titers have variable success rates. Imlifidase, a novel immunoglobulin G-degrading enzyme derived from Streptococcus pyogenes has been successfully used to eliminate pre-formed antibodies in sensitized kidney transplant recipients.
View Article and Find Full Text PDF